Tuesday, 04 October 2022

China: Hepatitis B vaccines not cause of deaths

07 January 2014 | News | By BioSpectrum Bureau

China has said that the suspension on production for key suppliers of Hepatitis B vaccine would continue

China has said that the suspension on production for key suppliers of Hepatitis B vaccine would continue

Singapore: Concluding an elaborate probe that started late last year, China has now said that the hepatitis B vaccines were not the cause of infant deaths.

It said that the nine deaths in infants were not caused by the hepatitis B virus inoculations, even as the suspension on production for key suppliers would continue.

The year started for the country's top three manufacturers with a suspension of manufacturing of their hepatitis B vaccines in the wake of the deaths. For more than a week, this move has sparked debate about a shortage that could come up following this.

Meanwhile, since Beijing Tiantan Biological Products, Shenzhen Kangtai Biological Products and Dalian Hissen Bio-Pharm have not been certified as meeting China's 2011 Good Manufacturing Practice (GMP) standards.

Reports pointed out that the new GMP rules place greater emphasis on the use of effective quality control system by pharmaceutical companies and introduce new standards on supplier audits, change control, raw material procurement and standard operating procedures.

Certification to the standards became mandatory for facilities manufacturing sterile drug products such as blood products, vaccines and other injectable drug products on December 31, 2013. Other facilities have to reach compliance by the end of 2015.

Late in 2013, China launched a probe into the safety of the vaccines after reports of 17 deaths in infants after receiving the inoculations came to light. In its preliminary findings, China found that the deaths were unrelated to the shots in nine cases, and look likely to be unrelated in the remaining eight. The authorities are now awaiting the results of autopsies in these cases.

The threat of shortage remains high in China amidst this, as the top three manufacturers account for upwards of 80 percent of the entire market for hepatitis B vaccines in the country.

Authorities in China have now insisted that there is no threat of a shortage in the near-term and increased production will be organized if it becomes necessary.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account